

2.5 Intellectual Property Management

PharmaEssentia established the “Intellectual Property Management and Utilization Procedures” to regulate the acquisition, protection, maintenance, and utilization of corporate intellectual property rights. Each year, the intellectual property management department at headquarters regularly reports on implementations for the previous year’s intellectual property management plan as well as the plan for the upcoming year to the Board. Implementations for the 2024 intellectual property management plan and the new intellectual property management plan for 2025 were reported to the Board on February 25, 2025. The Board helped to enhance corporate intellectual property strategies and protections, and effectively supervised protection measures for corporate intellectual property rights protections.

PharmaEssentia has gradually become an international pharmaceutical company, and therefore our frameworks and systems for controlling risks must also be

continuously improved. In 2024, we inventoried, reviewed, and updated longstanding R&D internal controls relating to intellectual property rights. These amendments were submitted to the Board for approval in early 2025 to comply with intellectual property risk control requirements for listed pharmaceutical companies.

The intellectual property department at PharmaEssentia headquarters has formulated a set of Group-wide intellectual property rights management policies which are being implemented at headquarters as well as all domestic and foreign subsidiaries. In 2024, we incurred no violations of intellectual property rights.

► Patent Positioning and Strategies

Decisions on whether to file patent applications for R&D results, as well as the regions/countries to file patents,

all adhere to PharmaEssentia procedures and are handled on a case-by-case basis. As there are differences in indications/patient types/market conditions for Ropeg and other new drugs being developed by PharmaEssentia, patent application requirements and application regions also differ. Apart from R&D highlights and output quality, we also consider various factors associated with marketing, manufacturing, local health insurance reimbursement conditions, accessibility, and regulatory requirements before making decisions on whether to apply for patents, as well as depth and breadth of patent strategies.

The intellectual property department at PharmaEssentia headquarters coordinates local access to medicine needs of all subsidiaries, and provides Group-level consultations and recommendations on supporting measures (such as authorizing drug imports and exports, prescriptions, and usage rights to specific regions as a patent holder to support necessary medical actions) so that the Group global operations team can appropriately plan feasible access to medicine solutions for all locales.

0 violations

In 2024, we incurred
no violations of intellectual
property rights



► PharmaEssentia Intellectual Property Rights Strategies

1. Continue to apply for and obtain invention patents in various countries

PharmaEssentia lays great emphasis on patent protections and patent management, and also has great respect for global patent protections and intellectual property rights. We protect new drug R&D achievements of R&D based pharmaceutical companies, continue to expand lifecycle protections and impacts of new drug products, and use these as a foundation for entering global markets.

2. Access to medicine considerations take priority over exercising patent rights for new drugs

We adjust our operational strategies based on patient needs and discrepancies in access to medicine for different locations. Least developed countries may be unable to afford or access new drugs due to intellectual property rights protections. Therefore, when exercising our drug patent rights, we not only consider the prevalence of said indication, local economic standards, and local governmental regulatory policies for new drugs, but also actual conditions of relatively low income countries and least developed countries to fulfill medication needs for local patients from the perspective of intellectual property rights. When we have to decide between enforcing patent rights for new drugs and humanitarian aid, we prioritize medical needs and offer accessible channels for obtaining medication and affordable prices to ensure that patients can obtain patented new drugs. In 2024, PharmaEssentia did not apply for or enforce patents in any low income countries or least developed countries.

3. Protection of intellectual property rights

As an international R&D based pharmaceutical company, PharmaEssentia has adopted many protection measures for core intellectual property rights since before the company was publicly listed. In terms of internal controls, we not only implement intellectual property rights procedures during R&D cycles, but also established the "Intellectual Property Management and Utilization Procedures" to regulate the acquisition, protection, maintenance, and utilization of intellectual property rights. Our R&D projects have gradually reached maturity and our products have gradually obtained marketing authorizations in different countries. Therefore, our R&D momentum has continued to expand and we are now facing a multitude of risks. Because of this, we made significant changes to internal controls associated with intellectual property rights procedures for our R&D cycles in 2024, and submitted these changes to the Board for approval in 2025.

To maintain the advantages of our core patent technologies, we adopt product life cycle management strategies to manage our intellectual property rights, and our R&D/manufacturing process and intellectual property teams continue to optimize existing patent technologies and explore related patents. We publicly disclose product optimization achievements as appropriate while extending protections for our product technologies as part of our contributions to society.

We have gradually obtained marketing authorizations around the globe and our commercial activities have also expanded, so there is a much higher risk of trademark infringements. When well-known trademarks are encroached upon by similar trademarks, the corporate brand value represented by the well-known trademark also decreases. PharmaEssentia expanded the functions of the intellectual property department and successfully implemented regular monitoring for similar trademarks around the globe to ensure management of global enterprises and brands. In 2024, shortly after implementing trademark monitoring measures, we successfully intercepted a trademark announcement in the US for a product with a name and indication that was very similar to Ropeg, which would have weakened our globally registered trademark if it had been registered and used on a similar product. Following advice from intellectual property attorneys, we filed a trademark opposition in the US within specified time limits as it was similar to our product and trademark. We effectively blocked the registration of said trademark and proved that global trademark monitoring measures provided solid intellectual property protections for our company.

► Specific Global Intellectual Property Protection Actions

PharmaEssentia

PharmaEssentia has conducted a comprehensive review and inventory of primary names, graphics and logos, and respective usage contexts for products and services representing the company, as well as respective international classes. Trademarks and logos that are being used commercially but which have not been registered were submitted in batches for trademark registration in Taiwan for full protection of trademarks registered for new drugs and to enhance the international brand image of new pharmaceutical companies in Taiwan.

PharmaEssentia USA

Trademarks for drug names were registered and protected prior to obtaining FDA marketing authorizations, and we gradually unveiled enterprise and product trademarks in various media channels after receiving marketing authorization and commenced management of our corporate brand. As the US adopts the first-to-use principle, we have to use our trademarks as soon as possible and deploy resources for registration of US trademarks as needed. All of our trademarks have been used for many years, and we will continue to register other representative trademarks to strengthen trademark protections for PharmaEssentia USA.

PharmaEssentia Japan

Regular monitoring reports are generated manually for Japanese trademarks that are not presented in English. We have not discovered any similar trademarks since we commenced monitoring measures.

► Intellectual Property Education and Training

Since PharmaEssentia expanded the general management division intellectual property department, internal US patent attorneys have conducted comprehensive internal intellectual property training each year to enhance patent knowledge in domestic and overseas R&D and intellectual property team personnel within the Group. In future, we plan to submit R&D results to the intellectual property department via a paper-free cloud platform. Therefore, in 2024, we conducted training courses on intellectual property management platform operations so the R&D department could submit R&D results in a timely manner. In order to align with global commercial developments for core products, we assessed the needs of PharmaEssentia headquarters and all subsidiaries, and conducted internal intellectual property training covering trademark registration, copyrights, and in-depth information on trade secrets and other intellectual properties. We are also planning regular promotion of our international intellectual property policies to all subsidiaries within the Group, to ensure that all personnel comply with related regulations.

Employee intellectual property education and training sessions conducted in 2024 were as follows:

Course title	Course format	Speakers	Targets	Participation hours per person
Progressiveness in patent law	Physical	Practicing US patent attorney	42 R&D, manufacturing process, and intellectual property personnel	1 hour
Drafting patent manuals	Physical (recorded content was made available online after the course)	PharmaEssentia US patent attorney	3 intellectual property department personnel from headquarters	2 hours
Introduction to "patent dance" in US patent law	Physical	PharmaEssentia US patent attorney	3 intellectual property department personnel from headquarters	2 hours
Training series introducing intellectual property management cloud platform	Online (rewatchable courses)	Intellectual property management cloud platform engineer and PM	3 intellectual property department personnel from headquarters	66 hours

► Patents and Trademarks

	Number of patents	Number of trademarks
Obtained (As of year-end 2024)	Cumulative number of valid patents: 242 in various countries and regions	Cumulative number of valid trademarks: 171 trademark certificates from various countries
Pending applications	23	17